Pharma BD Deal Intelligence
A $3.5B acquisition that gave Roche entry into MASH and severe hypertriglyceridemia through pegozafermin, a Phase 3 FGF21 analog, closing within six weeks of announcement. The all-cash-plus-CVR structure hedges Roche's bet on commercial milestones, though pivotal Phase 3 data doesn't read out until 2027-2028.
Roche on Thursday agreed to acquire 89bio, wagering that a medicine the biotechnology company is developing could offer a new way to treat a common liver…
Roche is buying 89bio to get pegozafermin, a drug currently in two Phase 3 studies for the fatty liver disease MASH. Beyond the $2.4 billion payable when the…
Regulatory documents show how 89bio's board pushed Roche hard for a deal valued at $20 per share in upfront and milestone payments. The success of Akero…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Roche acquired 89bio (Nasdaq: ETNB) in an all-cash tender offer announced September 17/18, 2025, paying $14.50 per share in cash (~$2.4 billion equity value) plus a non-tradeable contingent value right (CVR) of up to $6.00 per share (~$1.1 billion) tied to commercial milestones, for a total potential transaction value of approximately $3.5 billion. The deal gives Roche pegozafermin, a Phase 3 glycoPEGylated FGF21 analog, marking Roche's entry into metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Roche's tender offer expired October 29, 2025 and was not extended; the merger closed October 30, 2025, with 89bio becoming a wholly owned subsidiary of Roche and delisting from Nasdaq. Pegozafermin's Phase 3 ENLIGHTEN program (ENLIGHTEN-Fibrosis topline expected H1 2027; ENLIGHTEN-Cirrhosis 2028) continues under Roche, alongside the Phase 3 ENTRUST trial in SHTG.
F2/F3 MASH is the first-in-market MASH pharmacological opportunity, anchored by Rezdiffra (March 2024 approval) with FGF21 analogs and GLP-1-class agents in Phase 3 pursuit. THR-beta agonist (incumbent): resmetirom (Rezdiffra, Madrigal) — FDA-approved March 2024 specifically for non-cirrhotic F2/F3 MASH based on MAESTRO-NASH; Madrigal reported ~$137M net revenue H1 2024 per IR with multi-billion peak-sales consensus modeling. FGF21 analogs (direct MOA class, Phase 3): pegozafermin (89bio/Roche — Phase 3 ENLIGHTEN launched 2024 after Phase 2b ENLIVEN positive fibrosis regression signal); efruxifermin (EFX, Akero — Phase 3 SYNCHRONY after Phase 2b HARMONY positive readout); both compete head-on with resmetirom on fibrosis regression endpoint. GLP-1/GLP-1-GIP/triple agonists: semaglutide (Wegovy, Novo Nordisk — ESSENCE Phase 3 positive F2/F3 MASH resolution and fibrosis data 2024), tirzepatide (Zepbound, Eli Lilly — SYNERGY-NASH Phase 2 positive), survodutide (Boehringer — Phase 2 positive), retatrutide (Eli Lilly — Phase 2). FASN inhibitor: denifanstat (Sagimet — Phase 3 FASCINATE-3). SSAO/AOC3 inhibitor: BI 1467335 (Boehringer — discontinued). Commercial lead takeaway: pegozafermin enters a Rezdiffra-defended market where GLP-1 incretins can consume the metabolic-comorbid patient majority; Roche must differentiate on fibrosis depth and non-diabetic non-obese patients.
Compensated MASH cirrhosis (F4) is a high-unmet-need segment with NO approved pharmacotherapy and regulatory uncertainty on endpoint acceptance — a genuinely open franchise opportunity. THR-beta agonist (F2/F3 only, not F4): resmetirom (Rezdiffra, Madrigal) is explicitly NOT indicated for F4 cirrhosis; MAESTRO-NASH-OUTCOMES in F4 is ongoing with readout expected 2028. FGF21 analogs (F4 pipeline): pegozafermin (89bio/Roche — Phase 2b ENTRIGUE and cirrhosis-specific ENLIGHTEN-F4 enrollment 2024/2025); efruxifermin (EFX, Akero — Phase 2b SYMMETRY F4 readout late 2024, Phase 3 SYNCHRONY-Outcomes); both are direct head-to-head FGF21 competitors for the cirrhotic MASH label. GLP-1-class: semaglutide (Novo Nordisk — ESSENCE F2/F3 only; F4-specific trial paused historically); tirzepatide (Eli Lilly — SYNERGY-NASH enrolled only non-cirrhotic). Historical failures relevant to sizing: obeticholic acid (Ocaliva, Intercept — MASH NDA rejected 2020 and 2023, withdrawn from market 2024 for PBC cirrhosis on safety); selonsertib (ASK1, Gilead — failed STELLAR-4 F4); simtuzumab (LOXL2, Gilead — failed); cenicriviroc (CCR2/5, AbbVie/Allergan — discontinued). Anti-fibrotic investigational: tropifexor (Novartis — deprioritized), pegbelfermin (BMS — discontinued). Commercial lead takeaway: pegozafermin vs efruxifermin is the two-horse F4 race; whoever shows event-reduction (liver decompensation) first captures the fully unmet F4 segment.
Roche completed $3.5B acquisition of 89bio, gaining pegozafermin for MASH/NASH and severe hypertriglyceridemia liver disease programs.
Deal closed 2025 with pegozafermin in late-stage MASH development. Too early to evaluate; regulatory milestones expected 2026-2027.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / 89bio Inc. (this deal) | 2025 | $3.5B | 60 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2025 deals · Roche Holding AG deals · Gastroenterology deals